Answers are grounded in this paper and cite their sources.
Study implements DPYD genotyping to assess treatment modifications in cancer patients, indicating successful integration of pharmacogenomic testing.
e15139 Background: A subset of DPYD polymorphisms contribute to poor catabolism of fluoropyrimidines, resulting in increased risk of drug toxicity and even death. In 2025, the FDA recommended dihydropyrimidine dehydrogenase ( DPYD ) pharmacogenomic testing prior to fluoropyrimidine (FP) initiation. We describe implementation of mandatory DPYD testing into institutional workflow. Methods: DPYD pharmacogenomic testing was implemented 11/4/2025 at Memorial Sloan Kettering Cancer Center (MSK) prior to therapy with any FP using an in-house, CLIA and New York State approved blood-based assay. Testing of all 7 DPYD Tier 1 germline variants recommended by international professional societies was performed using a quantitative PCR-based approach (APIS Assay Technologies Ltd.) with results returned within 5 days from blood draw. We developed patient education materials, integrated New York State-required e-consent, notification to order testing, Genomic Indicator assignment, and hard stops preventing FP treatment verification and/or pharmacy release without DPYD results. A strategy for documenting exemptions and multidisciplinary communication was integrated into the Epic workflow. We describe implementation, detection rate, and treatment impact. Results: Among 604 tested patients, 27 (4.5%) harbored a DPYD polymorphism inclusive of patients with GI (n = 22), head and neck (n = 3), or breast (n = 2) cancers, with 20 receiving palliative intent treatment. Variants represented included c.1129-5923C > G (n = 19); c.1905+1G > A (n = 3), c.557A > G (n = 3), and c.868A > G (n = 2). 18 have had treatment modifications, 7 have had no treatment plan alteration and 2 are pending decisions. Among the 18 patients with altered treatment plans, 2 were prescribed non-FP regimens and 16 were administered FP dose-reductions ranging from 25-83% in dose-intensity for the first dose. Of the 16 who had dose-reduction, escalation after the first cycle was possible in 8 patients (4/8 to full dose). All patients tolerated therapy at initial and re-escalation doses without significant toxicity. Toxicities reported were dry mouth/lips (n = 2), diarrhea (n = 2), fatigue (n = 1), all grade 1 by CTCAE v5. Of the 7 patients where no treatment modification was initiated, 5 underwent testing in anticipation of future need for FP while 2 patients needed emergent treatment, both with intermediate DPYD activity who received full-dose therapy without exhibiting associated toxicity. Updated yield of universal DPYD testing and follow-up based on our experience through 4/2026 will be presented. Conclusions: MSK introduced mandatory e-consent and in-house DPYD testing prior to FP therapy in 11/2025. Polymorphisms were identified in 4.5% of the tested population and frequently led to treatment modifications. This implementation experience provides a framework for practices seeking to scale pharmacogenomic testing.
No takes yet. Share an insight, caveat, or question.
Maron et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: